Logo do repositório
 
Publicação

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

2025-03-12Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorKuksa, L.
dc.contributor.authorAndrejak, C.
dc.contributor.authorHaecker, B.
dc.contributor.authorBothamley, G.
dc.contributor.authorCalcagno, A.
dc.contributor.authorCirillo, D. M.
dc.contributor.authorDuarte, Raquel
dc.contributor.authorFatima, R.
dc.contributor.authorFerlazzo, G.
dc.contributor.authorGuglielmetti, L.
dc.contributor.authorGünther, G.
dc.contributor.authorHewison, C.
dc.contributor.authorHorsburgh, C.R.
dc.contributor.authorJäger, T.
dc.contributor.authorKalancha, Y.
dc.contributor.authorOtto-Knapp, R.
dc.contributor.authorKranzer, K.
dc.contributor.authorLillebaek, T.
dc.contributor.authorMarks, G.
dc.contributor.authorMiddelkoop, K.
dc.contributor.authorMotta, I.
dc.contributor.authorRabinova, V.
dc.contributor.authorSommerfeld, P.
dc.contributor.authorTattevin, P.
dc.contributor.authorLange, C.
dc.date.accessioned2026-02-13T12:29:57Z
dc.date.available2026-02-13T12:29:57Z
dc.date.issued2025-03-12
dc.descriptionEditorial
dc.description.abstractPretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, "when antibiotics used for the latter form of TB do not work or cause unacceptable side effects." This restricted use implies that the older, prolonged and poorly tolerated regimens remain the recommended treatment for most cases of drug-resistant TB. The authors, representing many respiratory groups and societies, call for the label expansion of pretomanid to align with global guidelines, allowing for broader use.eng
dc.identifier.citationIJTLD Open. 2025 Mar 12;2(3):117-119. doi: 10.5588/ijtldopen.25.0152. eCollection 2025 Mar
dc.identifier.doi10.5588/ijtldopen.25.0152
dc.identifier.eissn3005-7590
dc.identifier.pmid40092518
dc.identifier.urihttp://hdl.handle.net/10400.18/10933
dc.language.isoeng
dc.peerreviewedyes
dc.publisherInternational Union Against Tuberculosis and Lung Disease
dc.relation.hasversionhttps://journals.theunion.org/content/ijtldo/2/3/117
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectTuberculosis
dc.subjectDrug Resistance
dc.subjectMDR-TB
dc.subjectRR-TB
dc.subjectXDR-TB
dc.subjectWorld Health Organization
dc.subjectEuropean Medicines Agency
dc.subjectWHO European Region
dc.subjectInfecções Respiratórias
dc.subjectCuidados de Saúde
dc.subjectResistência aos Antimicrobianos
dc.titleUrgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacyeng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage119
oaire.citation.issue3
oaire.citation.startPage117
oaire.citation.titleIJTLD Open
oaire.citation.volume2
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Urgentrequestforpretomanidlabel_WHOguidelines_Kuksa_2025.pdf
Tamanho:
356.01 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

CD - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais